Phase 1 clinical trial of PMD-026 in metastatic cancer patients
Latest Information Update: 05 Dec 2020
At a glance
- Drugs PMD 026 (Primary)
- Indications Cancer
- Focus Adverse reactions
- Sponsors Phoenix Molecular Designs
- 05 Dec 2020 New trial record
- 24 Nov 2020 According to a Phoenix Molecular Designs media release, this study was completed in September of 2020.
- 24 Nov 2020 According to a Phoenix Molecular Designs media release, data from this study will be presented at the San Antonio Breast Cancer Conference Dec 8-12, 2020.